Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)

Next Previous
Trial Profile

A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Acute heart failure; Chronic heart failure; Decompensated heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPULSE
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 04 Aug 2023 Results comparing empagliflozin and placebo, stratified by baseline MRA use, published in the European Journal of Heart Failure
  • 06 Sep 2022 Results assessing the effect of empagliflozin on eGFR over time and the impact of baseline eGFR on the primary hierarchical outcome of death, worsening heart failure events and quality of life, published in the European Journal of Heart Failure.
  • 31 Aug 2022 According to a The Heart Failure Society of America media release, results from this trial will be presented at the The Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), which will take place September 30 - October 3, 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top